Instrument Inactif

Autres langues Kadimastem TEL AVIV STOCK EXCHANGE

Actions

KDST

IL0011284614

Recherche biotechnologique et médicale

Autres langues

31/07	NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing
31/07	NewcelX Ltd. announced that it expects to receive $1.399991 million in funding
15/07	NewcelX Obtains Patent in Brazil for Potential Type 1 Diabetes Treatment
15/07	NewcelX Granted Patent in Brazil for NCEL-101 in Type 1 Diabetes, Expanding Global IP Portfolio
08/07	Newcelx Ltd. Announces Appointment of Camillo Ricordi to Scientific Advisory Board
08/07	NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board
08/07	The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy
07/07	NewcelX Ltd. announced that it has received $2.940234 million in funding
01/07	NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes
01/07	NewcelX Ltd. Announces Successful FDA Pre-IND Meeting With Clear Path Forward For NCEL-101 Toward Starting Clinical Trials For Type 1 Diabetes
15/06	NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential Of Its Stem Cell Technology Platform
27/05	Newcelx submits pre-IND package to FDA for NCEL-101 for treatment of type 1 diabetes
27/05	NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes
27/05	NewcelX Submits Pre-IND Package To FDA For NCEL-101 For The Treatment Of Type 1 Diabetes
30/04	NewcelX Ltd. announced that it has received $1.349994 million in funding
30/04	NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026
29/04	NewcelX Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025
29/04	NewcelX Ltd. Auditor Raises 'Going Concern' Doubt
20/04	Newcelx updates corporate presentation to highlight type 1 diabetes flagship program
20/04	NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference
01/04	NewcelX Ltd. announced that it expects to receive $1.349994 million in funding
01/04	NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing
09/03	NewcelX announces strategic collaboration with Eledon Pharmaceuticals to advance NCEL-101 program for type 1 diabetes
09/03	NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes
12/02	NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy